Geode Capital Management
DRMA icon

Geode Capital Management’s Dermata Therapeutics DRMA Stock Holding History

Geode Capital Management’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Sell
20,203
-28,131
-58% -$35.4K ﹤0.01% 4351
2026
Q1 		$58.5K Buy
+48,334
New +$81.3K ﹤0.01% 4276
2025
Q3 		– Sell
-2,739
Closed -$16K – 4496
2025
Q2 		$16K Buy
2,739
+698
+34% +$5.35K ﹤0.01% 4388
2025
Q1 		$22K Buy
+2,041
New +$25.1K ﹤0.01% 4332
2024
Q2 		– Sell
-82
Closed -$4.92K – 4594
2024
Q1 		$4.92K Hold
82
– – ﹤0.01% 4587
2023
Q4 		$7.46K Hold
82
– – ﹤0.01% 4611
2023
Q3 		$13K Buy
+82
New +$15.7K ﹤0.01% 4694
2023
Q1 		– Sell
-11
Closed -$10K – 4811
2022
Q4 		$10K Hold
11
– – ﹤0.01% 4839
2022
Q3 		$13K Hold
11
– – ﹤0.01% 4960
2022
Q2 		$17K Hold
11
– – ﹤0.01% 4943
2022
Q1 		$33K Hold
11
– – ﹤0.01% 4886
2021
Q4 		$46K Buy
11
+4
+57% +$35.4K ﹤0.01% 4870
2021
Q3 		$71K Buy
+7
New +$82.8K ﹤0.01% 4735

Other funds holding DRMA

WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AA
Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Geode Capital Management's DRMA Position: Q2 2026 in Review

Geode Capital Management reduced its Dermata Therapeutics (DRMA) stake by 58% in Q2 2026, selling an estimated $35.4K and leaving 20,203 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4351.

Geode Capital Management first reported a position in DRMA in Q3 2021 and has held it in 13 quarters since. The position peaked at $71K in Q3 2021. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • Geode Capital Management held 20,203 shares of Dermata Therapeutics worth $26.1K as of Q2 2026.
  • Geode Capital Management sold 28,131 Dermata Therapeutics shares in Q2 2026, an estimated $35.4K.
  • Dermata Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4351 holding.
  • Geode Capital Management first reported a position in Dermata Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • Geode Capital Management's Dermata Therapeutics position peaked at $71K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.